PEL
MCID: LYM126
MIFTS: 44

Lymphoma Aids Related (PEL)

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymphoma Aids Related

MalaCards integrated aliases for Lymphoma Aids Related:

Name: Lymphoma Aids Related 20
Primary Effusion Lymphoma 20 58 17 70
Lymphoma, Aids-Related 17 70
Pel 20 58
Body Cavity-Based Lymphoma 58
Aids Related Lymphoma 20
Aids-Related Lymphoma 20
Lymphoma Aids-Related 54

Characteristics:

Orphanet epidemiological data:

58
primary effusion lymphoma
Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

MESH via Orphanet 45 D054685
ICD10 via Orphanet 33 C83.8
UMLS via Orphanet 71 C1292753
Orphanet 58 ORPHA48686
UMLS 70 C0085090 C1292753

Summaries for Lymphoma Aids Related

MalaCards based summary : Lymphoma Aids Related, also known as primary effusion lymphoma, is related to acquired immunodeficiency syndrome and lymphoma. An important gene associated with Lymphoma Aids Related is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Efavirenz and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include endothelial, b cells and t cells, and related phenotypes are abdominal pain and dyspnea

Wikipedia : 73 AIDS-related lymphoma describes lymphomas occurring in patients with acquired immunodeficiency syndrome... more...

Related Diseases for Lymphoma Aids Related

Diseases related to Lymphoma Aids Related via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 167)
# Related Disease Score Top Affiliating Genes
1 acquired immunodeficiency syndrome 30.3 MYC BCL6
2 lymphoma 30.2 TCL1A MYC BCL6
3 central nervous system lymphoma 30.0 MYC BCL6
4 plasmablastic lymphoma 30.0 MYC BCL6
5 b-cell lymphoma 29.9 TCL1A MYC BCL6
6 peripheral t-cell lymphoma 29.6 TCL1A BCL6
7 reticulosarcoma 29.6 MYC BCL6
8 mature b-cell neoplasm 29.5 MYC BCL6
9 mature t-cell and nk-cell lymphoma 29.5 MYC BCL6
10 lymphoma, non-hodgkin, familial 29.5 TCL1A MYC IL7 BCL6
11 t-cell lymphoblastic leukemia/lymphoma 29.5 TCL1A MYC
12 follicular lymphoma 29.4 MYC BCL6
13 burkitt lymphoma 29.3 TCL1A MYC IL7 BCL6
14 leukemia, acute myeloid 29.0 MYC IL7 BCL6
15 leukemia, chronic lymphocytic 28.6 TCL1A MYC IL7 BCL6
16 human immunodeficiency virus type 1 10.6
17 hemopericardium 10.6
18 pericardial effusion 10.6
19 lymphoma, hodgkin, classic 10.5
20 cardiac tamponade 10.4
21 liver cirrhosis 10.4
22 lymphoproliferative syndrome 10.4
23 hepatitis c virus 10.3
24 encephalopathy, progressive, with or without lipodystrophy 10.3
25 kaposi sarcoma 10.3
26 diffuse large b-cell lymphoma 10.3
27 primary central nervous system lymphoma 10.2
28 immune deficiency disease 10.2
29 myeloma, multiple 10.1
30 leukemia 10.1
31 hepatitis c 10.1
32 leukemia, t-cell, chronic 10.1
33 splenomegaly 10.1
34 rare tumor 10.1
35 adult t-cell leukemia 10.0
36 pleural tuberculosis 10.0
37 respiratory failure 10.0
38 lymphopenia 10.0
39 cytokine deficiency 10.0
40 kshv inflammatory cytokine syndrome 10.0
41 post-transplant lymphoproliferative disease 10.0
42 aggressive b-cell non-hodgkin lymphoma 10.0
43 human herpesvirus 8 10.0
44 nasopharyngeal carcinoma 10.0
45 pancytopenia 10.0
46 primary mediastinal b-cell lymphoma 9.9 TCL1A BCL6
47 retinoblastoma 9.9
48 anemia, autoimmune hemolytic 9.9
49 ascites, chylous 9.9
50 gastrointestinal stromal tumor 9.9

Graphical network of the top 20 diseases related to Lymphoma Aids Related:



Diseases related to Lymphoma Aids Related

Symptoms & Phenotypes for Lymphoma Aids Related

Human phenotypes related to Lymphoma Aids Related:

58 31 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
2 dyspnea 58 31 hallmark (90%) Very frequent (99-80%) HP:0002094
3 abnormality of the peritoneum 58 31 hallmark (90%) Very frequent (99-80%) HP:0002585
4 pleural effusion 58 31 hallmark (90%) Very frequent (99-80%) HP:0002202
5 abdominal distention 58 31 hallmark (90%) Very frequent (99-80%) HP:0003270
6 pericardial effusion 58 31 hallmark (90%) Very frequent (99-80%) HP:0001698
7 b-cell lymphoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0012191
8 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721

MGI Mouse Phenotypes related to Lymphoma Aids Related:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 8.8 BCL6 IL7 MYC

Drugs & Therapeutics for Lymphoma Aids Related

Drugs for Lymphoma Aids Related (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
2
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
3
Busulfan Approved, Investigational Phase 2 55-98-1 2478
4
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
5
Allopurinol Approved Phase 2 315-30-0 2094
6
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
7
Sulfamethoxazole Approved Phase 2 723-46-6 5329
8
Zidovudine Approved Phase 2 30516-87-1 35370
9
Trimethoprim Approved, Vet_approved Phase 2 738-70-5 5578
10
leucovorin Approved Phase 2 58-05-9 6006
11
Bleomycin Approved, Investigational Phase 2 11056-06-7 5360373
12
Fluorouracil Approved Phase 2 51-21-8 3385
13
Ifosfamide Approved Phase 2 3778-73-2 3690
14
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
15
Carmustine Approved, Investigational Phase 2 154-93-8 2578
16
Melphalan Approved Phase 2 148-82-3 4053 460612
17
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
18
Valganciclovir Approved, Investigational Phase 2 175865-60-8 64147
19
Bevacizumab Approved, Investigational Phase 2 216974-75-3
20
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
21
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
22
Lenograstim Approved, Investigational Phase 2 135968-09-1
23
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
24
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
26 Interleukin-12 Phase 2
27 Vitamin B9 Phase 2
28 Nutrients Phase 2
29 Micronutrients Phase 2
30 Trace Elements Phase 2
31 Cytochrome P-450 Enzyme Inhibitors Phase 2
32 Folate Phase 2
33 Vitamin B Complex Phase 2
34 Vitamins Phase 2
35 Folic Acid Antagonists Phase 2
36 Antidotes Phase 2
37 Trimethoprim, Sulfamethoxazole Drug Combination Phase 2
38 Antimalarials Phase 2
39 Antiparasitic Agents Phase 2
40 Antiprotozoal Agents Phase 2
41 Calcium, Dietary Phase 2
42 Reverse Transcriptase Inhibitors Phase 2
43 Anti-HIV Agents Phase 2
44
Isophosphamide mustard Phase 2 100427
45 Ganciclovir triphosphate Phase 2
46 Anti-Retroviral Agents Phase 2
47
Calcium Nutraceutical Phase 2 7440-70-2 271
48
Cortisone Experimental Phase 1 53-06-5 222786
49 Adjuvants, Immunologic Phase 1
50 Keratolytic Agents Phase 1

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Feasibility Study of CO-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of Acquired Immunodeficiency Syndrome (AIDS)-Related Lymphoma Completed NCT00799136 Phase 2 R-EPOCH and cART
2 EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma Completed NCT00001563 Phase 2 EPOCH
3 High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT Completed NCT00858793 Phase 1, Phase 2
4 Pilot Study of the Safety and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation for Patients With Relapsed AIDS-Related Lymphoma Completed NCT00005824 Phase 2 busulfan;cyclophosphamide
5 Study of Promace-Cytabom With Trimethoprim Sulfamethoxazole, Zidovudine (AZT), and Granulocyte Colony Stimulating Factor (G-CSF) in Patients With AIDS-Related Lymphoma, Phase II Completed NCT00002571 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;prednisone;trimethoprim-sulfamethoxazole;vincristine sulfate;Intrathecal cytarabine
6 Pilot Study in AIDS-Related Lymphomas Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)
7 First Line Treatment in HIV-related Large Cell Non Hodgkin Lymphoma at "High Risk", Including Early Consolidation With High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation Completed NCT01045889 Phase 2
8 Primary Effusion Lymphoma: A Pilot Trial of Bevacizumab and Modified Dose-Adjusted Infusional CDE Chemotherapy Preceded by a Brief Pre-Phase Assessment of Targeted Oncolytic Virotherapy With Bortezomib, Zidovudine and Valganciclovir Completed NCT00217503 Phase 2 bortezomib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ganciclovir;valganciclovir;zidovudine
9 Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R(2)) In Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma Recruiting NCT02911142 Phase 1, Phase 2 Lenalidomide;Rituximab;Prednisone;Etopside;Doxorubicin;Vincristine;Cyclophosphamide
10 Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas Active, not recruiting NCT00006436 Phase 2 EPOCH
11 Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa Active, not recruiting NCT01775475 Phase 2 cyclophosphamide;doxorubicin hydrochloride;vincristine sulfate;prednisone;lomustine;etoposide;cyclophosphamide;procarbazine hydrochloride
12 Multicenter, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab + CHOP Regimen in Patients With HIV Related Non-Hodgkin's Lymphomas. ANRS 085 Rituximab Terminated NCT00126243 Phase 2 rituximab;CHOP
13 Phase II Study of Induction Therapy Comprising Etoposide, Methylprednisolone, Cytarabine, and Cisplatin (ESHAP) Followed by Consolidation Therapy Comprising Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Withdrawn NCT00310128 Phase 2 cisplatin;cytarabine;etoposide;methylprednisolone;rituximab;yttrium Y 90 ibritumomab tiuxetan
14 Delayed Donor Leukocyte Infusions in Patients Receiving Allogeneic PBSC Following Conditioning With Non-myeloablative Regimen for AIDS-Related Lymphoma (NHL and HD) Withdrawn NCT00024128 Phase 2 cyclophosphamide;cyclosporine
15 Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease) Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
16 Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas Recruiting NCT03220022 Phase 1 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ibrutinib;Prednisone;Vincristine Sulfate
17 Autologous Transplantation and Stem Cell-Based Gene Therapy With LVsh5/C46 (CAL-1), a Dual Anti-HIV Lentiviral Vector, for the Treatment of HIV-Associated Lymphoma Withdrawn NCT02378922 Phase 1
18 A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines Completed NCT00001571
19 The Evaluation of Focal Contrast-Enhancing Brain Lesions in HIV-Infected Patients Completed NCT00226304
20 Oncogenic Viral Pathogenesis and Cancer Risk Factors Among Patients With the Acquired Immunodeficiency Syndrome: A Prospective Cohort Study Completed NCT00001120
21 French Cohort of HIV Associated Lymphomas Completed NCT01164436
22 Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy Completed NCT03690895
23 Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma Recruiting NCT02823327
24 Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies Available NCT02822495
25 AUTOLOGOUS TRANSPLANTATION AND STEM CELL BASED-GENE THERAPY FOR THE TREATMENT OF HIV-ASSOCIATED LYMPHOMA Withdrawn NCT01769911 carmustine;cytarabine;melphalan;etoposide;O6-benzylguanine

Search NIH Clinical Center for Lymphoma Aids Related

Genetic Tests for Lymphoma Aids Related

Anatomical Context for Lymphoma Aids Related

MalaCards organs/tissues related to Lymphoma Aids Related:

40
Endothelial, B Cells, T Cells, Lymph Node, Testis, Monocytes, Spleen

Publications for Lymphoma Aids Related

Articles related to Lymphoma Aids Related:

(show top 50) (show all 1301)
# Title Authors PMID Year
1
Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. 61
33720337 2021
2
3D culture conditions support Kaposi's sarcoma herpesvirus (KSHV) maintenance and viral spread in endothelial cells. 61
33484281 2021
3
Evidence for altered host genetic factors in KSHV infection and KSHV-related disease development. 61
33043529 2021
4
Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization. 61
33799222 2021
5
Induction of apoptosis by Shikonin through ROS-mediated intrinsic and extrinsic apoptotic pathways in primary effusion lymphoma. 61
33401054 2021
6
A Simple and Practical Guide for Triaging Lymphocyte-rich Effusions for Ancillary Studies. 61
33229932 2021
7
The anti-malaria agent artesunate exhibits cytotoxic effects in primary effusion lymphoma. 61
32885355 2021
8
Kaposi's Sarcoma-Associated Herpesvirus Processivity Factor, ORF59, Binds to Canonical and Linker Histones, and Its Carboxy Terminus Is Dispensable for Viral DNA Synthesis. 61
33361421 2021
9
Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases. 61
33669719 2021
10
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma. 61
33608378 2021
11
The cytopathological spectrum of lymphomas in effusions in a tertiary center in Taiwan. 61
32975910 2021
12
Human herpesvirus-8-positive primary effusion lymphoma in HIV-negative patients: Single institution case series with a multidisciplinary characterization. 61
32975904 2021
13
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen dysregulates expression of MCL-1 by targeting FBW7. 61
33471866 2021
14
High levels of LINE-1 transposable elements expressed in Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma. 61
33188297 2021
15
Novel Functions and Virus-Host Interactions Implicated in Pathogenesis and Replication of Human Herpesvirus 8. 61
33200369 2021
16
Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders. 61
33273183 2021
17
Kaposi's sarcoma-associated herpesvirus and extracellular vesicles. 61
33415746 2021
18
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2. 61
33411730 2021
19
IRE1 Alpha/XBP1 Axis Sustains Primary Effusion Lymphoma Cell Survival by Promoting Cytokine Release and STAT3 Activation. 61
33513694 2021
20
Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma. 61
33768081 2021
21
Without a silhouette. 61
33489219 2021
22
Suberoyl bis-hydroxamic acid reactivates Kaposi's sarcoma-associated herpesvirus through histone acetylation and induces apoptosis in lymphoma cells. 61
33328303 2020
23
A Fatal Case of Kaposi Sarcoma Immune Reconstitution Syndrome (KS-IRIS) Complicated by Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS) or Multicentric Castleman Disease (MCD): A Case Report and Review. 61
33268763 2020
24
Kaposi Sarcoma With Intravascular Primary Effusion Lymphoma in the Skin: A Potential Pitfall in HHV8 Immunohistochemistry Interpretation. 61
32460596 2020
25
CRISPR/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus. 61
33092788 2020
26
Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors. 61
33298918 2020
27
Diagnostic significance of adenosine deaminase in pleural effusate for primary effusion lymphoma-like lymphoma. 61
33363910 2020
28
Human herpesvirus 8-negative effusion-based lymphoma with indolent clinical behavior in an elderly patient: A case report and literature review. 61
33123254 2020
29
Developing new ceramide analogs and identifying novel sphingolipid-controlled genes against a virus-associated lymphoma. 61
32518949 2020
30
Widespread Traces of Lytic Kaposi Sarcoma-Associated Herpesvirus in Primary Effusion Lymphoma at Single-Cell Resolution. 61
33154001 2020
31
A CRISPR-Cas9 screen identifies mitochondrial translation as an essential process in latent KSHV infection of human endothelial cells. 61
33122441 2020
32
Nodal EBV-positive polymorphic B cell lymphoproliferative disorder with plasma cell differentiation: clinicopathological analysis of five cases. 61
33169195 2020
33
Extracavitary primary effusion lymphoma recurring with syphilis in an HIV-infected patient. 61
33148591 2020
34
Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism. 61
33245718 2020
35
A rare case of indolent B cell lymphoma with massive pleural effusion as the initial presentation. 61
33222449 2020
36
The spectrum of the cytopathological features of primary effusion lymphoma and human herpes virus 8-related lymphoproliferative disorders. 61
32171033 2020
37
Germinotropic lymphoproliferative disorder: a systematic review. 61
32307569 2020
38
Cytokine-Targeted Therapeutics for KSHV-Associated Disease. 61
32998419 2020
39
Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other KSHV-associated disorders. 61
32947593 2020
40
Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma. 61
32883022 2020
41
New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies. 61
32282911 2020
42
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). 61
32430507 2020
43
p300 promotes cell proliferation through suppressing Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation in the infected B-lymphoma cells. 61
32553609 2020
44
Evaluation of IL-2, IL-4, IL-6, IL-10, TNF-α, and IFN-γ cytokines in HIV/HHV-8 coinfection. 61
32926412 2020
45
Genetic Analyses of Contributions of Viral Interleukin-6 Interactions and Signaling to Human Herpesvirus 8 Productive Replication. 61
32669340 2020
46
Global epigenomic analysis of KSHV-infected primary effusion lymphoma identifies functional MYC superenhancers and enhancer RNAs. 61
32817485 2020
47
Regulation of KSHV Latency and Lytic Reactivation. 61
32957532 2020
48
Clinicopathologic characteristics and survival of patients with primary effusion lymphoma. 61
32449626 2020
49
KSHV LANA acetylation-selective acidic domain reader sequence mediates virus persistence. 61
32820070 2020
50
Productive herpesvirus lytic replication in primary effusion lymphoma cells requires S-phase entry. 61
32501196 2020

Variations for Lymphoma Aids Related

Copy number variations for Lymphoma Aids Related from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 25103 1 184000000 197500000 Gain primary effusion lymphomas
2 189792 4 78400000 172200000 Gain primary effusion lymphomas
3 239813 8 41800000 84900000 Gain primary effusion lymphomas
4 262574 X 37500000 98200000 Gain primary effusion lymphomas

Expression for Lymphoma Aids Related

Search GEO for disease gene expression data for Lymphoma Aids Related.

Pathways for Lymphoma Aids Related

Pathways related to Lymphoma Aids Related according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 MYC IL7 BCL6
2
Show member pathways
11.97 TCL1A MYC IL7
3 11.6 MYC BCL6
4 11.32 MYC BCL6
5 11.21 MYC BCL6
6
Show member pathways
10.27 MYC IL7

GO Terms for Lymphoma Aids Related

Biological processes related to Lymphoma Aids Related according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.43 TCL1A MYC IL7
2 positive regulation of B cell proliferation GO:0030890 9.16 IL7 BCL6
3 cytokine-mediated signaling pathway GO:0019221 9.13 MYC IL7 BCL6
4 negative regulation of apoptotic process GO:0043066 8.92 TCL1A MYC IL7 BCL6

Sources for Lymphoma Aids Related

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....